SCHEMBL440428

SCHEMBL440428

c1ccc(-c2cc(-c3ccccc3)c3ccc4c(-c5ccccc5)cc(-c5cccc6ccccc56)nc4c3n2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
MAPT P10636 4/20 0.45
KDM4E B2RXH2 3/20 0.45
ALDH1A1 P00352 3/20 0.45
HPGD P15428 3/20 0.45
MPI P34949 1/20 0.45
ACACA Q13085 3/20 0.43
ENPP3 O14638 1/20 0.43
ENPP1 P22413 1/20 0.43
MAPK1 P28482 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
TDP1 Q9NUW8 2/20 0.43
TP53 P04637 1/20 0.43
TSHR P16473 1/20 0.43
NFKB1 P19838 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
ATM Q13315 1/20 0.43
HSD17B10 Q99714 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3697659 0.97 MEN1 (0.49) MEN1KMT2AMAPTKDM4EALDH1A1
SCHEMBL13458738 0.94 MEN1 (0.47) MEN1KMT2AMAPTKDM4EALDH1A1
SCHEMBL13049750 0.94 ALDH1A1 (0.45) MEN1KMT2AMAPTKDM4EALDH1A1
SCHEMBL439435 0.94 ENPP3 (0.50) MEN1KMT2AMAPTKDM4EALDH1A1
SCHEMBL18101983 0.90 HPRT1 (0.45) MEN1KMT2AMAPTKDM4EALDH1A1
SCHEMBL3357426 0.90 ALDH1A1 (0.45) MEN1KMT2AMAPTKDM4EALDH1A1
SCHEMBL16696482 0.89 DHODH (0.45) MEN1KMT2AMAPTKDM4EALDH1A1
SCHEMBL16696470 0.88 DHODH (0.44) MEN1KMT2AMAPTKDM4EALDH1A1
SCHEMBL3700896 0.87 ENPP3 (0.43) MEN1KMT2AMAPTKDM4EALDH1A1
SCHEMBL5452946 0.87 TNF (0.44) MEN1KMT2AMAPTKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436341-B2 Electronic device including phenanthroline derivative E I DU PONT DE NEMOURS AND COMPANY (US) 2013-05-07 US disclosed
US-8436341-B2 Electronic device including phenanthroline derivative E I DU PONT DE NEMOURS AND COMPANY (US) 2013-05-07 US disclosed
US-8309731-B2 Electronic device including phenanthroline derivative E I DU PONT DE NEMOURS AND COMPANY (US) 2012-11-13 US disclosed
US-8309731-B2 Electronic device including phenanthroline derivative E I DU PONT DE NEMOURS AND COMPANY (US) 2012-11-13 US disclosed
US-20120065402-A1 ELECTRONIC DEVICE INCLUDING PHENANTHROLINE DERIVATIVE E.I.DU PONT DE NEMOURS AND COMPANY (US) 2012-03-15 US disclosed
US-20120065402-A1 ELECTRONIC DEVICE INCLUDING PHENANTHROLINE DERIVATIVE E.I.DU PONT DE NEMOURS AND COMPANY (US) 2012-03-15 US disclosed
US-20100207108-A1 ELECTRONIC DEVICE INCLUDING PHENANTHROLINE DERIVATIVE E. I. DU PONT DE NEMOURS AND COMPANY (US) 2010-08-19 US disclosed
US-20100207108-A1 ELECTRONIC DEVICE INCLUDING PHENANTHROLINE DERIVATIVE E. I. DU PONT DE NEMOURS AND COMPANY (US) 2010-08-19 US disclosed
WO-2010075379-A2 ELECTRONIC DEVICE INCLUDING PHENANTHROLINE DERIVATIVE E. I. DU PONT DE NEMOURS AND COMPANY (US) 2010-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065402-A1 ELECTRONIC DEVICE INCLUDING PHENANTHROLINE DERIVATIVE PAH, AHR, TYR MEN1 1950/4885KMT2A 1133/4885MAPT 3894/4885
US-20100207108-A1 ELECTRONIC DEVICE INCLUDING PHENANTHROLINE DERIVATIVE PAH, AHR, TYR MEN1 2122/4885KMT2A 1177/4885MAPT 3897/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.